share_log

Biodexa Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  May 15 18:50
Summary by Futu AI
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company listed on NASDAQ under the ticker BDRX, has announced the posting of its Annual Report and the Notice of its upcoming Annual General Meeting (AGM). The AGM is scheduled to take place at the company's Cardiff office on June 13, 2024, at 12.00 noon BST. Shareholders have been provided with details on proxy voting in the Notice of AGM. The company, which specializes in developing treatments for diseases with unmet medical needs, has also disclosed its total voting rights, amounting to 2,238,225,722 Ordinary Shares, with no shares held in treasury. Biodexa's lead development programs include eRapa for Familial Adenomatous Polyposis and Non Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for rare/orphan brain cancer indications. The company's proprietary drug delivery technologies aim to enhance the bio-delivery and bio-distribution of medicines. The Annual Report and AGM Notice are available on the Biodexa Pharmaceuticals website.
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company listed on NASDAQ under the ticker BDRX, has announced the posting of its Annual Report and the Notice of its upcoming Annual General Meeting (AGM). The AGM is scheduled to take place at the company's Cardiff office on June 13, 2024, at 12.00 noon BST. Shareholders have been provided with details on proxy voting in the Notice of AGM. The company, which specializes in developing treatments for diseases with unmet medical needs, has also disclosed its total voting rights, amounting to 2,238,225,722 Ordinary Shares, with no shares held in treasury. Biodexa's lead development programs include eRapa for Familial Adenomatous Polyposis and Non Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for rare/orphan brain cancer indications. The company's proprietary drug delivery technologies aim to enhance the bio-delivery and bio-distribution of medicines. The Annual Report and AGM Notice are available on the Biodexa Pharmaceuticals website.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.